Lotefort Ophthalmic Suspension contains Loteprednol etabonate 0.5% w/v, a corticosteroid indicated for the treatment of inflammatory conditions of the eye, including allergic conjunctivitis, anterior uveitis, and postoperative inflammation following ocular surgery. Loteprednol etabonate exhibits potent anti-inflammatory properties by inhibiting the release of inflammatory mediators and suppressing the immune response, thereby reducing redness, swelling, and discomfort. The suspension formulation ensures uniform distribution of the active ingredient upon instillation into the conjunctival sac. Lotefort is typically administered as one to two drops in the affected eye(s) four times daily, with dosage adjustments based on clinical response and severity of inflammation. Caution is advised in patients with a history of glaucoma, as corticosteroids may increase intraocular pressure. Prolonged use should be avoided unless under strict medical supervision to prevent potential adverse effects such as cataract formation or secondary ocular infections. Patients should be monitored regularly for signs of ocular hypertension and infection. Lotefort Ophthalmic Suspension is contraindicated in viral, fungal, or mycobacterial eye infections. Proper aseptic techniques should be employed to avoid contamination of the suspension. This medication should be used only as prescribed by a qualified ophthalmologist or healthcare professional.